{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T14:10:13Z","timestamp":1756303813590,"version":"3.44.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,27]]},"DOI":"10.7759\/cureus.91104","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T13:34:35Z","timestamp":1756301675000},"source":"Crossref","is-referenced-by-count":0,"title":["Assessment of Immunohistochemical Expression of Cluster of Differentiation 44 (CD44) in Breast Carcinoma"],"prefix":"10.7759","author":[{"given":"Ranu","family":"Kumari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satish G","family":"Arakeri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sai","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.21608\/ejhm.2019.30955","article-title":"Immunohistochemical expression of cyclooxygenase- 2 (COX-2) in breast cancer","volume":"75","author":"Nassar MI","year":"2019","unstructured":"Nassar MI, Bebars SM, Said RM, Mustafa TM. Immunohistochemical expression of cyclooxygenase- 2 (COX-2) in breast cancer. Egypt J Hospital Med. 2019, 75:2397- 405. 10.21608\/ejhm.2019.30955","journal-title":"Egypt J Hospital Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15194794","article-title":"The possible role of anti-and protumor-infiltrating lymphocytes in pathologic complete response in early breast cancer patients treated with neoadjuvant systemic therapy","volume":"15","author":"Ger\u0161ak K","year":"2023","unstructured":"Ger\u0161ak K, Ger\u0161ak BM, Gazi\u0107 B, Ivan\u010di\u010d AK, Drev P, Gorenjec NR, Kuhar CG. The possible role of anti-and protumor-infiltrating lymphocytes in pathologic complete response in early breast cancer patients treated with neoadjuvant systemic therapy. Cancers (Basel). 2023, 15:10.3390\/cancers15194794","journal-title":"Cancers (Basel)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray F","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024, 74:229-63. 10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2217\/whe.15.99","article-title":"Breast cancer subtypes: morphologic and biologic characterization","volume":"12","author":"Masood S","year":"2016","unstructured":"Masood S. Breast cancer subtypes: morphologic and biologic characterization. Womens Health (Lond). 2016, 12:103-19. 10.2217\/whe.15.99","journal-title":"Womens Health (Lond)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S316700","article-title":"The characteristics of tumor microenvironment in triple negative breast cancer","volume":"14","author":"Fan Y","year":"2022","unstructured":"Fan Y, He S. The characteristics of tumor microenvironment in triple negative breast cancer. Cancer Manag Res. 2022, 14:1-17. 10.2147\/CMAR.S316700","journal-title":"Cancer Manag Res"},{"key":"ref6","doi-asserted-by":"crossref","DOI":"10.5152\/cjms.2021.2711","article-title":"Immunohistochemical expression of COX 2 and its relationship with prognostic parameters in breast cancer","volume":"6","author":"Tekin L","year":"2021","unstructured":"Tekin L, Celik SY. Immunohistochemical expression of COX 2 and its relationship with prognostic parameters in breast cancer. Cyprus J Med Sci. 2021, 6:39-43.","journal-title":"Cyprus J Med Sci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/2561726","article-title":"Clinical impact of breast cancer stem cells in metastatic breast cancer patients","volume":"2020","author":"Elbaiomy MA","year":"2020","unstructured":"Elbaiomy MA, Akl T, Atwan N, Elsayed AA, Elzaafarany M, Shamaa S. Clinical impact of breast cancer stem cells in metastatic breast cancer patients. J Oncol. 2020, 2020:2561726. 10.1155\/2020\/2561726","journal-title":"J Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1089\/omi.2021.0025","article-title":"Cancer stem cell marker CD44 plays multiple key roles in human cancers: immune suppression\/evasion, drug resistance, epithelial-mesenchymal transition, and metastasis","volume":"25","author":"Dzobo K","year":"2021","unstructured":"Dzobo K, Sinkala M. Cancer stem cell marker CD44 plays multiple key roles in human cancers: immune suppression\/evasion, drug resistance, epithelial-mesenchymal transition, and metastasis. OMICS. 2021, 25:313-32. 10.1089\/omi.2021.0025","journal-title":"OMICS"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/biom11121850","article-title":"CD44: a multifunctional mediator of cancer progression","volume":"11","author":"Hassn Mesrati M","year":"2021","unstructured":"Hassn Mesrati M, Syafruddin SE, Mohtar MA, Syahir A. CD44: a multifunctional mediator of cancer progression. Biomolecules. 2021, 11:10.3390\/biom11121850","journal-title":"Biomolecules"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-14364-2","article-title":"Unraveling the roles of CD44\/CD24 and ALDH1 as cancer stem cell markers in tumorigenesis and metastasis","volume":"7","author":"Li W","year":"2017","unstructured":"Li W, Ma H, Zhang J, Zhu L, Wang C, Yang Y. Unraveling the roles of CD44\/CD24 and ALDH1 as cancer stem cell markers in tumorigenesis and metastasis. Sci Rep. 2017, 7:13856. 10.1038\/s41598-017-14364-2","journal-title":"Sci Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13174287","article-title":"Breast cancer-epidemiology, risk factors, classification, prognostic markers, and current treatment strategies-an updated review","volume":"13","author":"\u0141ukasiewicz S","year":"2021","unstructured":"\u0141ukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanis\u0142awek A. Breast cancer-epidemiology, risk factors, classification, prognostic markers, and current treatment strategies-an updated review. Cancers (Basel). 2021, 13:10.3390\/cancers13174287","journal-title":"Cancers (Basel)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/513158","article-title":"Molecular markers for breast cancer: prediction on tumor behavior","volume":"2014","author":"Banin Hirata BK","year":"2014","unstructured":"Banin Hirata BK, Oda JM, Losi Guembarovski R, Ariza CB, de Oliveira CE, Watanabe MA. Molecular markers for breast cancer: prediction on tumor behavior. Dis Markers. 2014, 2014:513158. 10.1155\/2014\/513158","journal-title":"Dis Markers"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2108","article-title":"The CD44+\/CD24- phenotype is enriched in basal-like breast tumors","volume":"10","author":"Honeth G","year":"2008","unstructured":"Honeth G, Bendahl PO, Ringn\u00e9r M, et al.. The CD44+\/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res. 2008, 10:R53. 10.1186\/bcr2108","journal-title":"Breast Cancer Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.31557\/APJCP.2020.21.9.2561","article-title":"Predictive value of CD44 for prognosis in patients with breast cancer","volume":"21","author":"Roosta Y","year":"2020","unstructured":"Roosta Y, Sanaat Z, Nikanfar AR, Dolatkhah R, Fakhrjou A. Predictive value of CD44 for prognosis in patients with breast cancer. Asian Pac J Cancer Prev. 2020, 21:2561-7. 10.31557\/APJCP.2020.21.9.2561","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djab202","article-title":"The incidence of breast cancer recurrence 10-32 years after primary diagnosis","volume":"114","author":"Pedersen RN","year":"2022","unstructured":"Pedersen RN, Esen B\u00d6, Mellemkj\u00e6r L, et al.. The incidence of breast cancer recurrence 10-32 years after primary diagnosis. J Natl Cancer Inst. 2022, 114:391-9. 10.1093\/jnci\/djab202","journal-title":"J Natl Cancer Inst"},{"key":"ref16","article-title":"Association of CD44 and CD24 phenotype with lymph node metastasis and survival in triple-negative breast cancer","volume":"13","author":"Zou W","year":"2020","unstructured":"Zou W, Yang Y, Zheng R, et al.. Association of CD44 and CD24 phenotype with lymph node metastasis and survival in triple-negative breast cancer. Int J Clin Exp Pathol. 2020, 13:1008-16.","journal-title":"Int J Clin Exp Pathol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.31083\/j.ejgo.2020.01.4810","article-title":"Stem cells in ductal breast cancer: immunohistochemical expression of CD44, CD24, CD133, and ALDH-1 markers in 104 cases","volume":"62","author":"Korfias D","year":"2020","unstructured":"Korfias D, Contis J, Frangou-Plemenou M, Gennatas K, Kondis A, Vlachodimitropoulos D. Stem cells in ductal breast cancer: immunohistochemical expression of CD44, CD24, CD133, and ALDH-1 markers in 104 cases. Eur J Gynaecol Oncol. 2020, 62:2943. 10.31083\/j.ejgo.2020.01.4810","journal-title":"Eur J Gynaecol Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.4103\/ijpm.ijpm_437_21","article-title":"Role of CD44 as cancer stem cell marker in triple-negative breast cancer and its association with histological grade and angiogenesis","volume":"66","author":"Tomar R","year":"2023","unstructured":"Tomar R, Rakheja G, Verma N, Thakur S, Khurana N, Ghuliani D. Role of CD44 as cancer stem cell marker in triple-negative breast cancer and its association with histological grade and angiogenesis. Indian J Pathol Microbiol. 2023, 66:258-63. 10.4103\/ijpm.ijpm_437_21","journal-title":"Indian J Pathol Microbiol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2021.1950927","article-title":"Expression of markers of stem cell characteristics, epithelial-mesenchymal transition, basal-like phenotype, proliferation, and androgen receptor in metaplastic breast cancer and their prognostic impact","volume":"60","author":"Voutilainen S","year":"2021","unstructured":"Voutilainen S, Heikkil\u00e4 P, Sampo M, Nevanlinna H, Blomqvist C, Mattson J. Expression of markers of stem cell characteristics, epithelial-mesenchymal transition, basal-like phenotype, proliferation, and androgen receptor in metaplastic breast cancer and their prognostic impact. Acta Oncol. 2021, 60:1233-9. 10.1080\/0284186X.2021.1950927","journal-title":"Acta Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/379741-assessment-of-immunohistochemical-expression-of-cluster-of-differentiation-44-cd44-in-breast-carcinoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T13:34:36Z","timestamp":1756301676000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/379741-assessment-of-immunohistochemical-expression-of-cluster-of-differentiation-44-cd44-in-breast-carcinoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,27]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.91104","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,27]]}}}